Journal article

Authors list: Weber, Theresa; Schmitz, Roland

Publication year: 2022

Pages: 13-21

Journal: Current Oncology Reports

Volume number: 24

Issue number: 1

ISSN: 1523-3790

eISSN: 1534-6269

Open access status: Hybrid

DOI Link: https://doi.org/10.1007/s11912-021-01155-2

Publisher: Springer

Abstract: 
Purpose of Review Genomic analyses have immensely advanced our conception of the heterogeneity of diffuse large B cell lymphoma (DLBCL), resulting in subgroups with distinct molecular profiles. In this review, we summarize our current knowledge of the biology of DLBCL complexity and discuss the potential implications for precision medicine. Recent Findings During the last two decades, gene expression profiling, copy number analysis, and high throughput sequencing enabled the identification of molecular subclasses of DLBCL that are biologically and clinically meaningful. The resulting classifications provided novel prospects of diagnosis, prognostication, and therapeutic strategies for this aggressive disease. The molecular characterization of DLBCL offers unprecedented insights into the biology of these lymphomas that can guide precision medicine. The knowledge of the molecular setup of an individual DLBCL patients enables prognostication of patients and will be useful to stratify patients in clinical trials. Future direction should focus to implement the molecular classifications of DLBCL in the clinical practice to evaluate their significance and scope using real-world data.

Harvard Citation style: Weber, T. and Schmitz, R. (2022) Molecular Subgroups of Diffuse Large B Cell Lymphoma: Biology and Implications for Clinical Practice, Current Oncology Reports, 24(1), pp. 13-21. https://doi.org/10.1007/s11912-021-01155-2

APA Citation style: Weber, T., & Schmitz, R. (2022). Molecular Subgroups of Diffuse Large B Cell Lymphoma: Biology and Implications for Clinical Practice. Current Oncology Reports. 24(1), 13-21. https://doi.org/10.1007/s11912-021-01155-2